A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

NCT00693186 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B

Interventions

BIOLOGICAL: HBVaxPRO® 5 µg / 0.5 mL
BIOLOGICAL: Engerix B® 10 µg / 0.5 mL

Sponsor

Sanofi Pasteur, a Sanofi Company